FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Court Rules Mylan, Chemical Companies Must Pay Insurers $67 Million

Sept. 7, 2017
A A

A District of Columbia federal court ruled Mylan Pharmaceuticals and two chemical companies must pay $67 million to Blue Cross Blue Shield of Massachusetts and three other insurers in a long-running suit that accused the companies of antitrust violations.

BCBS Massachusetts, BCBS of Minnesota, Health Care Service Corp. and Federated Insurance Co. were successful in a court case in 2005, that accused the drugmaker and chemical manufacturers of violating antitrust laws in connection with its licensing agreements with the two ingredient manufacturers.

The defendants sought a new trial based on objections to the calculation of damages awarded to customers of the plaintiffs. Those customers were subsequently dismissed from the case.

View today's stories